Immuron Limited · ASX:IMC
Immuron — Investor Presentation (November 2023)
11 slides from Immuron's investor presentation, Nov 13, 2023
Slide 1: Immuron Investor Webinar
IMMUren 14 NOVEMBER, 2023 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as yu “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expres
Slide 3: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Financial Snapshot Shares on Issue 227,798,346 Total Options |
Slide 4: Distribution Capability
DISTRIBUTION CAPABILITY Australia USA Canada Retail Pharmacy <7 A B2B Vv 2 <a @ Established E-commerce 4 aS aS @A Developing Australia * Retail network includes over 3,500 pharmacies * Online sales of both Travelan® and Protectyn® * Protectyn?® is distributed by Osborne Health Supplies USA * Travela
Slide 5: Strong Sales Growth
nm Siemon PRore! STRONG SALES GROWTH oe cALLY PROVEN. v Traveller’s Diarrhoea (TD) Market is large and growing ~7% 3 CAGR Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent 30% - 70% of travelers experience TD 4 Bie .*. Australia x. 12 months to July 2023 short ter
Slide 6: Technology Platform for Gut Mediated Diseases
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES © Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to
Slide 7: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs Compound or Indication Phase Phase Phase Market brand name I MW ul IMM-124E Traveler's Travelan® Diarrhea ETEC |((\MMULQ, challenge Clostridioides difficile Infection & Im mute) Recurrence Our Partners’ Clinical Programs Compound
Slide 8: Valuable Sales Potential for Pipeline Products
VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS ©) » — Immuron’s development of IMM-124E (hyperimmune > — Infectious disease experts reacted favorably to the IMM-529 bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the potential to address
Slide 9: Near Term Milestones Anticipated to Drive Value
NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 FDA IND? approved for single daily dose IMM-124E ETEC? 1H 2023 IRB Approval* Initiated IMM-124E ETEC? CHIM? 2H 2023 100% of patients enrolled Completion of In-patient phase © Topline results for IMM-124E ETEC? clinical trial 1H 20 Travelan® CHI
Slide 10: Contact Information
ImmMuUren STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM &D PHONE: AUSTRALIA: +613 8892 4854
Slide 11: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers 46:7-8, 862-868, DOI: Journal of 10.3109/00365521.2011.574726 Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Trav